These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15085235)

  • 1. Incorporation of isoniazid into liposomes with different lipid composition.
    Sorokoumova GM; Selishcheva AA; Malikova NM; Minina AS; Shvets VI
    Bull Exp Biol Med; 2004 Jan; 137(1):17-9. PubMed ID: 15085235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation.
    Otto-Knapp R; Vesenbeckh S; Schönfeld N; Bettermann G; Roth A; Bauer T; Rüssmann H; Mauch H
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1275-6. PubMed ID: 27510258
    [No Abstract]   [Full Text] [Related]  

  • 3. Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.
    Leidinger P; Treptow J; Hagens K; Eich J; Zehethofer N; Schwudke D; Oehlmann W; Lünsdorf H; Goldmann O; Schaible UE; Dittmar KE; Feldmann C
    Angew Chem Int Ed Engl; 2015 Oct; 54(43):12597-601. PubMed ID: 26332072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of the efficiency of activity of the liposomal form of isoniazid against different types of mycobacteria in vitro].
    Golyshevskaia VI; Selishcheva AA; Martynova LP; Lepekha LN; Kalashnikova TM; Kornilova ZKh; Erokhin VV; Rozenberg OA
    Probl Tuberk Bolezn Legk; 2006; (8):61-4. PubMed ID: 17002062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis.
    Campanerut-Sá PA; Ghiraldi-Lopes LD; Meneguello JE; Fiorini A; Evaristo GP; Siqueira VL; Scodro RB; Patussi EV; Donatti L; Souza EM; Cardoso RF
    Future Microbiol; 2016 Sep; 11():1123-32. PubMed ID: 27545345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.
    Yadav AB; Misra A
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3740-2. PubMed ID: 17664326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
    Shrivastava P; Gautam L; Sharma R; Dube D; Vyas S; Vyas SP
    J Microencapsul; 2021 Mar; 38(2):108-123. PubMed ID: 33267623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Complex research studies in the testing of the effectiveness of phenaside].
    Sel'tsovskiĭ PP; Irtuganova OA; Slogotskaia LV; Smirnova NS; Moroz AM; Borzenko AS; Spasov AA; Smirnova LA; Dzhura PI; Karpov AV; Ivanovskiĭ VB; Pauker MN; Plemiannikova GI
    Probl Tuberk; 2001; (8):29-31. PubMed ID: 11767386
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthesis, characterization and in-vitro antitubercular activity of isoniazid-gelatin conjugate.
    Cassano R; Trombino S; Ferrarelli T; Cavalcanti P; Giraldi C; Lai F; Loy G; Picci N
    J Pharm Pharmacol; 2012 May; 64(5):712-8. PubMed ID: 22471367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOTS in Haiti.
    Ollé-Goig JE
    Int J Tuberc Lung Dis; 2000 Mar; 4(3):282-3. PubMed ID: 10751080
    [No Abstract]   [Full Text] [Related]  

  • 11. Isoniazid: A Review of Characteristics, Properties and Analytical Methods.
    Fernandes GFDS; Salgado HRN; Santos JLD
    Crit Rev Anal Chem; 2017 Jul; 47(4):298-308. PubMed ID: 28080136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of liposomes containing 4-(5-pentadecyl-1,3,4-oxadiazol-2-yl)pyridine in a murine model of progressive pulmonary tuberculosis.
    Mata-Espinosa D; Molina-Salinas GM; Barrios-Payán J; Navarrete-Vázquez G; Marquina B; Ramos-Espinosa O; Bini EI; Baeza I; Hernández-Pando R
    Pulm Pharmacol Ther; 2015 Jun; 32():7-14. PubMed ID: 25843004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid activity is terminated by bacterial persistence.
    Mitchison DA; Jindani A; Davies GR; Sirgel F
    J Infect Dis; 2007 Jun; 195(12):1871-2; author reply 1872-3. PubMed ID: 17492605
    [No Abstract]   [Full Text] [Related]  

  • 14. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis.
    Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2004 Apr; 23(4):414-5. PubMed ID: 15081096
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effectiveness of antibacterial preparations incorporated into liposomes in the treatment of experimental tuberculosis].
    Kurunov IuN; Nikolin VP; Kaledin VI; Matienko NA; Budker VG
    Probl Tuberk; 1982 Oct; (10):54-8. PubMed ID: 7178105
    [No Abstract]   [Full Text] [Related]  

  • 17. Concomitant increases in spectrum and level of drug resistance in Mycobacterium tuberculosis isolates.
    Sun Z; Zhang J; Song H; Zhang X; Li Y; Tian M; Liu Y; Zhao Y; Li C
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1436-41, i. PubMed ID: 20937184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid-resistant cavitary tuberculosis in a physician following isoniazid prophylaxis.
    Karchmer TB; Phipps JD; Giannetta ET; Farr BM
    Infect Control Hosp Epidemiol; 2002 Oct; 23(10):622-5. PubMed ID: 12400895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction to a formal theory of the dosage regimen calculation in intermittent chemotherapy of tuberculosis.
    Bercea O; Bonciocat N
    Arzneimittelforschung; 1970 Feb; 20(2):241-5. PubMed ID: 4986038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.